Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olipudase alfa in pediatric acid sphingomyelinase deficiency
2014-003198-40Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Primary endpoint: Number of adverse events. Started Nov 2014; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on 2014-003198-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003198-40.